Skip to main content
Premium Trial:

Request an Annual Quote

Nine New RNAi-Related Patent Applications Published by USPTO

Premium

Title: Novel Human Proteins, Polynucleotides encoding them, and Methods of Using the Same. Number: 20030229016. Filed: Dec. 2, 2002. Lead Inventor: John Alsobrook II, Yale University School of Medicine.

This patent application, its abstract states, covers nucleic acid sequences that encode novel polypeptides, and the polypeptides themselves. It also covers antibodies that immunospecifically bind to the polypeptides, as well as derivatives, variants, mutants, or fragments of the polypeptide, polynucleotide, or antibody specific to the polypeptide.

The patent application adds that the invention “also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual.” The method comprises “administrating to that individual an RNAi construct that targets the mRNA of the protein for degradation,” the application states. “A specific RNAi construct includes an siRNA or double-stranded gene transcript that is processed into siRNAs.”


Title: Antibodies Having Specificity for Nucleic Acids. Number: 20030228590. Filed: Feb. 12, 2003. Lead Inventor: Susan Radka, Sirna Therapeutics.

This patent application, states its abstract, relates to “antibodies, antibody conjugates, and compositions thereof, methods of antibody synthesis, and applications of antibodies useful for detecting the presence of nucleic acid molecules in vivo, such as a clinical setting.”

The abstract adds that the antibodies are also useful as screening agents for therapeutic candidates, and as delivery agents for nucleic acid molecules.


Title: Methods to Increase or Decrease Bone Density. Number: 20030229041. Filed: Feb. 28, 2003. Lead Inventor: May Kung Sutherland, Celltech.

The patent application’s abstract states that the invention “provides antagonists to the sclerostin protein and methods for identifying new sclerostin antagonists.” The application also covers molecules that can depress expression of the SOST gene, which gives rise to sclerostin, and methods for identifying such molecules, the abstract adds.

The patent application also provides a method for inhibiting SOST expression by RNAi, a process that involves introducing “RNA with partial or fully double-stranded character into the cell or extracellular environment.”


Title: Transfection Method and Uses Related Thereto. Number: 20030228694. Filed: March 4, 2003. Inventor: David Sabatini, Whitehead Institute.

This patent application, its abstract states, covers “a method of introducing nucleic acid molecules into eukaryotic cells by depositing a nucleic acid molecule-containing mixture onto a surface; affixing the … mixture to the surface; [and] plating eukaryotic cells onto the surface under appropriate conditions for entry of the nucleic acid molecules into the cells.”


Title: Modulation of Tumor Cells Using BER Inhibitors in Combination with a Sensitizing Agent and DSBR Inhibitors. Number: 20030229004. Filed: March 20, 2003. Lead Inventor: David Zarling, Pangene.

According to the patent application’s abstract, the invention includes a method of contacting a target cell with both a BER inhibitor and a sensitizing agent, such as a chemotherapeutic drug. Cells may also be contacted with a DSBR inhibitor, such as a RAD inhibitor.

The application also provides for an siRNA or RNAi molecule as a BER inhibitor.


Title: Materials and Methods for the Modification of Plant Cell Wall Polysaccharides. Number: 20030229922. Filed: March 20, 2003. Inventor: Leonard Bloksberg, Genesis Research and Development.

The patent application, its abstract states, provides for “novel isolated polynucleotides and polypeptides associated with the synthesis of plant cell wall polysaccharides, [as well as] genetic constructs comprising such sequences” and methods of their use.

The application notes that “polynucleotides of the present invention may … be used to specifically suppress gene expression by methods that operate post-transcriptionally to block the synthesis of products of targeted genes, such as RNA interference and quelling.”


Title: Transfection Methods and Uses Related Thereto. Number: 20030228601. Filed: March 28, 2003. Inventor: David Sabatini, Whitehead Institute.

This patent application, states its abstract, covers an invention featuring “a method of identifying a nucleic acid molecule capable of post-transcriptional gene silencing by affixing a plurality [of] nucleic acid molecules onto a surface in discrete, defined locations; contacting eukaryotic cells with the affixed nucleic acid molecules under appropriate conditions for entry of the … molecules into the cells … and determining the ability of the nucleic acid molecules to post-transcriptionally silence expression of a gene in the cells.”


Title: Methods and Compositions for the Treatment of Disorders of HIV Infection. Number: 20030229906. Filed: April 14, 2003. Lead Inventor: Irwin Gelman, Roswell Park Cancer Institute.

The invention, states the patent application’s abstract, “relates to methods and compositions for use in the intervention of diseases associated with HIV infection,” such as HIV-associated nephropathy.

According to the application, “the present invention provides methods and compositions for decreasing, inhibiting, or otherwise abrogating the interaction of Nef with an SH3 domain of a Src family tyrosine kinase.”

This Nef/Src interaction may be disrupted through “the use of nucleic acid-based techniques to block the expression of Nef,” the application adds. “Polynuelcotide gene products which are useful in this endeavor include antisense polynucleotides, ribozymes, [and] RNAi.”


Title: Processes for Inhibiting Gene Expression Using Polynucleotides. Number: 20030228691. Filed: May 19, 2003. Lead Inventor: David Lewis, Mirus.

This patent application, its abstract states, covers a process “for inhibition of specific gene expression in an animal cell by delivering a combination of RNA function inhibitors.”

The process can be used to reduce gene expression in vitro and in vivo, the abstract notes.

The application states that the invention covers a gene expression inhibition process “comprising delivering to a cell a combination of two or more RNA function inhibitors specific to the gene … wherein at least one of the RNA function inhibitors induces RNA interference.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.